Date/Time: Friday, October 9, 2020 - 3:30 PM – 5:30 PM
Track: Special Interest Group
Log in to Add to My Schedule


The  incidence of neurologic autoimmune disorders in the context of wider use of anti-cancer immunotherapies is increasing. Immune checkpoint inhibitors and CAR-T cells  interrupt mechanisms involved in prevention of auto-immunity or have pro-inflammatory properties. As a result, a wide-ranging spectrum of neurologic inflammatory adverse events  have  emerged  posing diagnostic and therapeutic challenges that neurologists  need to address. Immunotherapies are also an area of active investigation in patients with primary brain tumors. This session will review advances in immunotherapy of primary brain tumors and discuss neurologic complications of cancer and cancer therapies. The rationale for targeting the immune system in brain tumor therapy and the results of ongoing trials  will be discussed.  The mechanisms underlying neurologic  adverse  effects,  and their diagnosis and management will be reviewed.


  • To recognize strategies to identify and manage cancer related auto-immunity and the unique adverse events related  to use of anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies and CAR-T cell therapies.

  • To describe the rationale for targeting the immune system in the treatment of brain tumors.

  • To evaluate results of ongoing clinical trials examining immunotherapy agents as part of  treatment paradigms.


Brain Tumor Immunotherapy

First Dose Pembrolizumab-induced Toxicity in Young Patient Treated for Invasive Thymoma: An Overlap Syndrome of Myasthenia Gravis and Myositis

Paraneoplastic Syndromes and Neurologic Autoimmunity in the era of Cancer Immunotherapy

Pre-infusion neurofilament light chain (NfL) levels predict the development of immune effector cell-associated neurotoxicity syndrome (ICANS)

Update on Car-T Cell Neurotoxicity